CRYSTAL HUMPHRIES: Open Payments
NPI 1700882131 · SPARTANBURG, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,699 in 80 payments from 29 companies in 2025. Trend: 2023 $2,375 · 2024 $1,580 · 2025 $1,699
Food & beverage: $1,621Education: $78
| Company | Payments | Amount |
|---|---|---|
| Celgene Corporation | 12 | $276 |
| Incyte Corporation | 6 | $167 |
| Janssen Biotech, Inc. | 8 | $152 |
| Daiichi Sankyo Inc. | 6 | $147 |
| E.R. Squibb & Sons, L.L.C. | 5 | $98 |
| AstraZeneca Pharmaceuticals LP | 4 | $77 |
| ABBVIE INC. | 4 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| SOBI, INC | 3 | $52 |
| GlaxoSmithKline, LLC. | 3 | $49 |
Products named: OPDIVO, REBLOZYL, Enhertu, OPDUALAG, IMBRUVICA, ERLEADA, JAKAFI, KEYTRUDA.
Industry payments across SC — which companies pay providers there.
